\
&
Contact us
\
&
Contact us
Published on | 2 years ago
Programmes MSCAA total of 1066 proposals were submitted in response to the MSCA Doctoral Networks 2023 call with proposal submission deadline on 28 November 2023. The number of proposals for each topic is shown below:
- Doctoral Networks (standard DN): 920 proposals (86.3% of total)
- Industrial Doctorates (DN-ID): 64 proposals (6.0% of total)
- Joint Doctorates (DN-JD): 82 proposals (7.7% of total)
Source: Funding and Tender Portal
More information on the number of coordinators per country that submitted a proposal and an indicative timeline of the evaluation process can be found in the European Commission MSCA news article
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Deployment: Best use of technologies
Please note that the European Commission has extended the deadline for call DIGITAL-2025-BESTUSE-TECH-09 with the following two call topics: European Digital Identity Wallet EU Mobile Driving Licences) NEW closing date: 15 January 2026 (previously 09 December 2025) read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
